Clinical Edge Journal Scan

Risk of 5-year local recurrence declines with event-free years in newly diagnosed breast cancer


 

Key clinical point: In patients with newly diagnosed breast cancer (BC), the risk of local recurrence (LR) as a first event within 5 years of diagnosis was low and declined further with the number of event-free years.

Major finding: Overall, the incidence of LR as a first event within 5 years of diagnosis was 3.0%, which decreased to 2.4%, 1.6%, 1.0%, and 0.6% after 1, 2, 3, and 4 event-free years, respectively.

Study details : Findings are from the nationwide Netherlands Cancer Registry database, including 34,453 patients with newly diagnosed breast cancer between 2005 and 2008.

Disclosures: This study was supported by CZ fonds 201400316. ML Smidt reported receiving grant from Servier Pharma. Other authors had no disclosures.

Source: Moossdorff M et al. Breast Cancer Res Treat. 2021 Mar 10. doi: 10.1007/s10549-020-06040-3 .

Recommended Reading

Could tamoxifen dose be slashed down to 2.5 mg? 
MDedge Hematology and Oncology
Huge, struggling breast cancer screening trial gets lifeline
MDedge Hematology and Oncology
Risk-based mammography proposed for times of reduced capacity
MDedge Hematology and Oncology
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic risk
MDedge Hematology and Oncology
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic risk
MDedge Hematology and Oncology
Pembrolizumab fails to improve OS in patients with previously treated metastatic TNBC
MDedge Hematology and Oncology
Node-negative ER+/HER2− breast cancer: Adjuvant ET improves OS in older patients with comorbidities
MDedge Hematology and Oncology
Advanced breast cancer: Palbociclib+ET associated with low burden of cutaneous toxicities
MDedge Hematology and Oncology
Breast MRI less accurate in predicting nodal status after neoadjuvant therapy in invasive lobular carcinoma
MDedge Hematology and Oncology
Link between reproductive factors and breast cancer incidence
MDedge Hematology and Oncology